GYREGYRE THERAPEUTICS, INC.vs its industry peers
A metric-by-metric comparison of GYRE THERAPEUTICS, INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GYRE본 종목 | $749M#7 | — | 6.9x#12 | 6.4x#5 | 10.2%#6 | -44.8%#14 | 9.9%#4 | 9.2%#5 | 12.0%#4 | 3#3 | -9.2%#7 | 6.0%#1 |
| CYRX | $836M#1 | — | 1.7x#1 | 4.7x#4 | 12.4%#5 | 168.2%#5 | -20.9%#5 | 16.0%#4 | -16.5%#5 | 4#1 | 83.2%#3 | — |
| GERN | $832M#2 | — | 3.8x#7 | 3510.6x#10 | -60.2%#9 | 52.2%#6 | -28938.8%#10 | -38.2%#10 | -24.8%#6 | — | — | — |
| RIGL | $831M#3 | 2.6x#1 | 2.0x#2 | 2.8x#3 | 64.1%#3 | 1999.1%#2 | 42.6%#1 | 86.3%#1 | 30.6%#3 | — | 27.0%#6 | — |
| CLYM | $810M#4 | — | 3.4x#6 | — | — | 19.0%#8 | — | -25.0%#8 | — | — | — | — |
| ACRS | $784M#5 | — | 6.3x#11 | 100.2x#9 | -58.2%#8 | 50.8%#7 | -975.9%#8 | -52.1%#12 | -65.8%#7 | 3#3 | 190.2%#1 | — |
| DSGN | $783M#6 | — | 3.9x#8 | — | — | -40.7%#13 | — | -34.6%#9 | — | — | — | — |
| COLL | $723M#8 | 17.5x#4 | 2.3x#3 | 0.9x#1 | 23.6%#4 | -8.7%#10 | 23.0%#3 | 20.2%#3 | 62.0%#1 | 4#1 | -37.7%#9 | — |
| NVCT | $712M#9 | — | 78.4x#14 | — | — | -39.2%#12 | — | -291.1%#13 | — | — | — | — |
| ZVRA | $701M#10 | 12.7x#3 | 3.2x#5 | 6.6x#6 | 350.9%#1 | 178.9%#4 | -59.1%#6 | 38.2%#2 | — | — | — | — |
| NGNE | $695M#11 | — | 3.2x#4 | — | -100.0%#10 | -20.2%#11 | — | -41.6%#11 | — | — | 99.9%#2 | — |
| IRWD | $690M#12 | 5.3x#2 | — | 2.3x#2 | -15.7%#7 | 2629.5%#1 | 33.3%#2 | — | 42.6%#2 | — | — | — |
| MNPR | $679M#13 | — | 5.2x#10 | — | — | 12.0%#9 | — | -10.5%#7 | — | — | 77.8%#4 | — |
| VSTM | $665M#14 | — | 13.3x#13 | 21.5x#7 | 209.1%#2 | -60.3%#15 | -550.3%#7 | -419.1%#14 | — | — | -19.5%#8 | — |
| CBIO | $637M#15 | — | 3.9x#9 | 58.7x#8 | — | 306.4%#3 | -1407.5%#9 | 0.1%#6 | — | — | 37.1%#5 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice